October 24, 2017
COLUMBIA CITY, Ind.–(BUSINESS WIRE)–Sites Medical, a firm specializing in value-driven innovation in orthopedics, today announced it has entered into a licensing agreement with Integrity Implants, to incorporate its proprietary OsteoSync™ Ti technology into Integrity’s novel multi-dimensional expandable interbody devices.
“We are thrilled to be partnering with Integrity Implants, a company with a high degree of innovation in the spine field and an accomplished leadership team,” said Greg Stalcup, President/CEO of Sites Medical. “We look forward to working with the Integrity team to combine our respective technologies to deliver a new generation of high performance, high value products to the market.”
OsteoSync™ Ti technology is a highly porous titanium scaffold designed to meet the needs of today’s patients from both clinical and economic standpoints. Its high friction coefficient ensures high initial implant stability and its open pore geometry and micro-texturing facilitate superior bone ingrowth. Preclinical testing has demonstrated bone attachment strength nearly twice that of titanium plasma spray and approximately seven times that of PEEK material at the 5-week follow up period, a performance differential that can impact clinical outcomes, especially in spinal fusion patients. OsteoSync™ Ti technology has also been engineered to reduce the potential for abrasion during implant insertion and associated debris-related inflammation, offering an additional measure of safety for the patient. The material is manufactured using highly innovative methods and offers substantial value in today’s cost-conscious healthcare environment.
“We are very excited to work with Sites Medical,” said Wyatt Geist, President & CTO of Integrity Implants. “As the market begins to recognize the need for implants that promote better short- and long-term stability, the Sites Medical OsteoSync™ Ti technology offers us an opportunity to provide proven bone ingrowth capability at cost-effective levels. Together with our unique expandable technology, our devices will offer state-of-the-art capabilities for surgeons to help promote better clinical outcomes. We look forward to showing our first devices featuring this unique technology at NASS.”
About Sites Medical
Sites Medical has recognized the shift in healthcare reimbursement paradigms and is entirely focused on Value-Driven Innovation in orthopedics. With its suite of proprietary orthopedic implant technologies and manufacturing process improvements, Sites aims to deliver improved clinical outcomes and reduced cost to all stakeholders. Additional information about the company can be found at www.sitesmedical.com.
About Integrity Implants
Founded in 2016, Integrity Implants focuses on unique expandable interbody technology. The FlareHawk family of expandable interbodies are the world’s first to expand in height, width and lordosis. Additional information about the company and product can be found at www.integrityimplants.com.